The New Math Of Ortho Innovation – An Interview With Zimmer CEO David Dvorak

After emerging from the DOJ settlements, the leading pure-play orthopedics company is emphasizing – and redefining – innovation to drive growth. Zimmer CEO David Dvorak talks to IN VIVO about his company’s commitment to innovation, and how the very notion of innovation is changing.

Given everything that’s happened in the years since, it’s easy to forget that less than a decade ago, the US orthopedics industry was caught in the throes of a major investigation by the US Department of Justice (DOJ) and coping with the terms of the subsequent settlement with the US Attorney’s Office. And though both the investigation and the settlement affected all of the top US-based orthopedics companies – only Stryker Corp. was not part of the original settlement group – Zimmer Biomet Holdings Inc. stood out. Not only was the company cited for having the largest number of high-priced consulting agreements – the first public postings of surgeon consulting contracts post-settlement showed that there were 47 contracts worth more than $1 million, and Zimmer held 21 of them – it paid the most in fines of the four that eventually became part of the settlement. (See Also see "Orthopedics Settlement: Puts the Issue to Bed--Or Does It? " - In Vivo, 1 November, 2007..)How long ago that all seems now. The conflict of interest and related issues that roiled the industry – though in truth more orthopedics executives were happy about the investigation and its subsequent restrictions than were unhappy – now seem a distant memory. Certainly, the adoption of rigorous compliance programs, both at individual companies and across the industry, helped put any concerns about undue influence and improper behavior to rest. But much more than that, in the intervening years, a host of new dynamics – first a major global economic crisis, followed by continued cost pressures in health care and a major health care reform effort in the US, as well as the emergence of new markets in places like China and India – have made the issues raised by the DOJ investigations seem, if not irrelevant, then at least far less pressing than they did in the mid-2000s.

In short, the new reality that the COI investigations were supposed to usher in has been replaced by a new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.